Brittani Thomas, DO
Hematology & Oncology · Lansing, MINPI 1972940179
Payments from drug & device makers
Across 320 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$500
- Genentech USA, Inc.$415
- AstraZeneca$411
- Bristol Myers Squibb$348
- Gilead$302
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,64676%
- Education$6469%
- Other$1,09715%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 75 | $2,125 |
| Amgen | 19 | $500 |
| Genentech USA, Inc. | 23 | $415 |
| AstraZeneca(2 entities) | 17 | $411 |
| Bristol Myers Squibb | 17 | $348 |
| Gilead(2 entities) | 13 | $302 |
| Pfizer | 18 | $279 |
| Seagen Inc. | 11 | $272 |
| Lilly USA, LLC | 12 | $271 |
| Astellas Pharma US Inc | 9 | $235 |
| Eisai Inc. | 10 | $198 |
| Merck | 8 | $178 |
| Sirtex Medical Inc | 1 | $148 |
| Daiichi Sankyo Inc. | 7 | $148 |
| GSK | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| AbbVie | 5 | $121 |
| Johnson & Johnson | 6 | $117 |
| Servier Pharmaceuticals LLC | 6 | $105 |
| Array Biopharma Inc | 6 | $102 |
| Puma Biotechnology, Inc. | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Sanofi | 5 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $74 |
| Stemline Therapeutics Inc. | 3 | $72 |
| Agios Pharmaceuticals, Inc. | 3 | $63 |
| Incyte Corporation | 3 | $60 |
| Foundation Medicine, Inc. | 2 | $53 |
| Beigene USA, Inc. | 2 | $45 |
| Tersera Therapeutics LLC | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $38 |
| Sobi, Inc | 2 | $34 |
| Acrotech Biopharma Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| EMD Serono, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,388 in reported general payments places this provider in the 65th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 47 | $697,524 |
| Lenalidomide | 23 | $400,597 |
| PomalystPomalidomide | 14 | $310,132 |
| CalquenceAcalabrutinib Maleate | 21 | $306,896 |
| KisqaliRibociclib Succinate | 18 | $302,722 |
| BrukinsaZanubrutinib | 23 | $251,378 |
| RevlimidLenalidomide | 13 | $229,009 |
| Abiraterone Acetate | 34 | $175,903 |
| XtandiEnzalutamide | 12 | $141,359 |
| EliquisApixaban | 89 | $94,845 |
| XareltoRivaroxaban | 41 | $38,711 |
| Imatinib Mesylate | 13 | $36,521 |
| Anastrozole | 254 | $12,663 |
| Exemestane | 58 | $11,008 |
| Tamoxifen Citrate | 70 | $2,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $279 | $792,369136 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $87 | $310,13214 claims |
| AstraZenecaCalquence | $411 | $306,89621 claims |
| NovartisKisqali | $2,125 | $302,72218 claims |
| Beigene USA, Inc.Brukinsa | $45 | $251,37823 claims |
| Bristol Myers SquibbRevlimid | $348 | $229,00913 claims |
| Astellas Pharma US IncXtandi | $235 | $141,35912 claims |
| Johnson & JohnsonXarelto | $117 | $38,71141 claims |
| Lilly USA, LLCOlanzapine | $271 | $31653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Lansing
- Gordon SrkalovicLansing$692K
- Borys HrinczenkoLansing$404K
- Daniel IsaacLansing$152K
- Muhammad HamdanLansing$58K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.